NRSN
NASDAQ · Biotechnology
Neurosense Therapeutics Ltd
$0.72
+0.01 (+1.42%)
Open$0.72
Previous Close$0.71
Day High$0.73
Day Low$0.70
52W High$2.28
52W Low$0.63
Volume—
Avg Volume209.6K
Market Cap26.77M
P/E Ratio—
EPS$-0.62
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+4,793.1% upside
Current
$0.72
$0.72
Target
$35.23
$35.23
$27.84
$35.23 avg
$57.14
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.58M | 1.62M | 1.28M |
| Net Income | 134.3K | 163.7K | 131.8K |
| Profit Margin | 8.5% | 10.1% | 10.3% |
| EBITDA | 233.3K | 224.5K | 177.5K |
| Free Cash Flow | 149.0K | 201.8K | 175.9K |
| Rev Growth | +15.5% | +19.0% | +13.7% |
| Debt/Equity | 0.19 | 0.18 | 0.19 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |